Activating frataxin expression by single-stranded siRNAs targeting the GAA repeat expansion

Xiulong Shen, Audrius Kilikevicius, Daniel O'Reilly, Thazha P. Prakash, Masad J. Damha, Frank Rigo, David R. Corey

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Friedreich's ataxia (FRDA) is an incurable neurodegenerative disorder caused by reduced expression of the mitochondrial protein frataxin (FXN). The genetic cause of the disease is an expanded GAA repeat within the FXN gene. Agents that increase expression of FXN protein are a potential approach to therapy. We previously described anti-trinucleotide GAA duplex RNAs (dsRNAs) and antisense oligonucleotides (ASOs) that activate FXN protein expression in multiple patient derived cell lines. Here we test two distinct series of compounds for their ability to increase FXN expression. ASOs with butane linkers showed low potency, which is consistent with the low Tm values and suggesting that flexible conformation impairs activity. By contrast, single-stranded siRNAs (ss-siRNAs) that combine the strengths of dsRNA and ASO approaches had nanomolar potencies. ss-siRNAs provide an additional option for developing nucleic acid therapeutics to treat FRDA.

Original languageEnglish (US)
Pages (from-to)2850-2855
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Volume28
Issue number17
DOIs
StatePublished - Sep 15 2018

Fingerprint

Antisense Oligonucleotides
Friedreich Ataxia
Inborn Genetic Diseases
Mitochondrial Proteins
RNA
Neurodegenerative Diseases
Nucleic Acids
Conformations
Proteins
Genes
Cells
frataxin
Cell Line
Therapeutics

Keywords

  • Antisense oligonucleotides
  • Frataxin
  • Friedreich's ataxia
  • Gene activation
  • ss-siRNAs

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Activating frataxin expression by single-stranded siRNAs targeting the GAA repeat expansion. / Shen, Xiulong; Kilikevicius, Audrius; O'Reilly, Daniel; Prakash, Thazha P.; Damha, Masad J.; Rigo, Frank; Corey, David R.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 28, No. 17, 15.09.2018, p. 2850-2855.

Research output: Contribution to journalArticle

Shen, Xiulong ; Kilikevicius, Audrius ; O'Reilly, Daniel ; Prakash, Thazha P. ; Damha, Masad J. ; Rigo, Frank ; Corey, David R. / Activating frataxin expression by single-stranded siRNAs targeting the GAA repeat expansion. In: Bioorganic and Medicinal Chemistry Letters. 2018 ; Vol. 28, No. 17. pp. 2850-2855.
@article{73c1923a9bbe41ba8da08a04ce57cebd,
title = "Activating frataxin expression by single-stranded siRNAs targeting the GAA repeat expansion",
abstract = "Friedreich's ataxia (FRDA) is an incurable neurodegenerative disorder caused by reduced expression of the mitochondrial protein frataxin (FXN). The genetic cause of the disease is an expanded GAA repeat within the FXN gene. Agents that increase expression of FXN protein are a potential approach to therapy. We previously described anti-trinucleotide GAA duplex RNAs (dsRNAs) and antisense oligonucleotides (ASOs) that activate FXN protein expression in multiple patient derived cell lines. Here we test two distinct series of compounds for their ability to increase FXN expression. ASOs with butane linkers showed low potency, which is consistent with the low Tm values and suggesting that flexible conformation impairs activity. By contrast, single-stranded siRNAs (ss-siRNAs) that combine the strengths of dsRNA and ASO approaches had nanomolar potencies. ss-siRNAs provide an additional option for developing nucleic acid therapeutics to treat FRDA.",
keywords = "Antisense oligonucleotides, Frataxin, Friedreich's ataxia, Gene activation, ss-siRNAs",
author = "Xiulong Shen and Audrius Kilikevicius and Daniel O'Reilly and Prakash, {Thazha P.} and Damha, {Masad J.} and Frank Rigo and Corey, {David R.}",
year = "2018",
month = "9",
day = "15",
doi = "10.1016/j.bmcl.2018.07.033",
language = "English (US)",
volume = "28",
pages = "2850--2855",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "17",

}

TY - JOUR

T1 - Activating frataxin expression by single-stranded siRNAs targeting the GAA repeat expansion

AU - Shen, Xiulong

AU - Kilikevicius, Audrius

AU - O'Reilly, Daniel

AU - Prakash, Thazha P.

AU - Damha, Masad J.

AU - Rigo, Frank

AU - Corey, David R.

PY - 2018/9/15

Y1 - 2018/9/15

N2 - Friedreich's ataxia (FRDA) is an incurable neurodegenerative disorder caused by reduced expression of the mitochondrial protein frataxin (FXN). The genetic cause of the disease is an expanded GAA repeat within the FXN gene. Agents that increase expression of FXN protein are a potential approach to therapy. We previously described anti-trinucleotide GAA duplex RNAs (dsRNAs) and antisense oligonucleotides (ASOs) that activate FXN protein expression in multiple patient derived cell lines. Here we test two distinct series of compounds for their ability to increase FXN expression. ASOs with butane linkers showed low potency, which is consistent with the low Tm values and suggesting that flexible conformation impairs activity. By contrast, single-stranded siRNAs (ss-siRNAs) that combine the strengths of dsRNA and ASO approaches had nanomolar potencies. ss-siRNAs provide an additional option for developing nucleic acid therapeutics to treat FRDA.

AB - Friedreich's ataxia (FRDA) is an incurable neurodegenerative disorder caused by reduced expression of the mitochondrial protein frataxin (FXN). The genetic cause of the disease is an expanded GAA repeat within the FXN gene. Agents that increase expression of FXN protein are a potential approach to therapy. We previously described anti-trinucleotide GAA duplex RNAs (dsRNAs) and antisense oligonucleotides (ASOs) that activate FXN protein expression in multiple patient derived cell lines. Here we test two distinct series of compounds for their ability to increase FXN expression. ASOs with butane linkers showed low potency, which is consistent with the low Tm values and suggesting that flexible conformation impairs activity. By contrast, single-stranded siRNAs (ss-siRNAs) that combine the strengths of dsRNA and ASO approaches had nanomolar potencies. ss-siRNAs provide an additional option for developing nucleic acid therapeutics to treat FRDA.

KW - Antisense oligonucleotides

KW - Frataxin

KW - Friedreich's ataxia

KW - Gene activation

KW - ss-siRNAs

UR - http://www.scopus.com/inward/record.url?scp=85050657731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050657731&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2018.07.033

DO - 10.1016/j.bmcl.2018.07.033

M3 - Article

C2 - 30076049

AN - SCOPUS:85050657731

VL - 28

SP - 2850

EP - 2855

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 17

ER -